Termination of domestic licensing agreements for six anti-HIV drugs
First written in FY2018. 1 of 4 entries say "Achieved", first in FY2019. Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019AchievedAnnual report
「The licensing agreement between us, Gilead and 鳥居薬品 for the exclusive development and commercialization rights in Japan for 6 anti-HIV drugs ended on 1 January 2019, and the transfer of the marketing authorizations to Gilead Sciences K.K., Gilead's Japanese subsidiary, was completed on 1 December of the same year.」
Following the termination of the domestic licensing agreement for 6 anti-HIV drugs, the transfer of the marketing authorizations was also completed on 1 December 2019. - FY2019-Q2Continued revenue impact from contract termination and recognition of gain on transferAnnual report
「Revenue declined 21.4% year on year due to the termination of the domestic licensing agreement for 6 anti-HIV drugs, among other factors. Gain on transfer of pharmaceutical licenses: 60,518.」
The revenue decline in the pharmaceutical business resulting from the termination of the domestic licensing agreement for 6 anti-HIV drugs continued, resulting in a 21.4% year-on-year decline, while a gain on transfer of the licenses under the agreement of ¥60.518 billion was recorded in other operating income. - FY2019-Q1Financial impact of contract termination becomes apparentAnnual report
「Revenue declined 14.6% year on year due to the termination of the domestic licensing agreement with the partner company for 6 anti-HIV drugs, among other factors.」
The revenue decline resulting from the termination of the domestic licensing agreement for 6 anti-HIV drugs emerged in the first-quarter results of the pharmaceutical business as a 14.6% year-on-year decline. - FY2018First statedAnnual report
「The licensing agreement between the Company, Gilead Sciences Inc. (hereinafter, “Gilead”) and Torii Pharmaceutical for the exclusive development and commercialisation rights in Japan for 6 anti-HIV drugs, including Descovy combination tablets, ended on 1 January 2019. This agreement is hereinafter referred to as the “Original Agreement.”」
The company stated that the licensing agreement for exclusive development and commercialisation rights in Japan for 6 anti-HIV drugs ended on 1 January 2019. Transitional trading terms applied after the agreement ended until the marketing authorisation was transferred.